LeishMan Recommendations for Treatment of Cutaneous and Mucosal Leishmaniasis in Travelers, 2014

Authors

  • Johannes Blum MD,

    Corresponding author
    1. Swiss Tropical and Public Health Institute, Basel, Switzerland
    2. University of Basel, Basel, Switzerland
    3. TropNet, European Network for Tropical Medicine and Travel Health, Basel, Switzerland
    • Corresponding Author: Johannes A. Blum, MD, Swiss Tropical and Public Health Institute, Socinstrasse 57, 4002 Basel, Switzerland. E-mail: johannes.blum@unibas.ch

    Search for more papers by this author
  • Pierre Buffet MD,

    1. UMRs945 INSERM UPMC Immunity & Infection, Paris, France
    2. Service de Parasitologie-Mycologie, Hôpital Pitié Salpêtrière, Paris, France
    3. University Pierre et Marie Curie, Paris, France
    Search for more papers by this author
  • Leo Visser MD,

    1. TropNet, European Network for Tropical Medicine and Travel Health, Basel, Switzerland
    2. Leiden University Medical Centre, Leiden, The Netherlands
    Search for more papers by this author
  • Gundel Harms MD,

    1. Institute of Tropical Medicine and International Health, Charité - Universitätsmedizin Berlin, Berlin, Germany
    Search for more papers by this author
  • Mark S. Bailey MD,

    1. Royal Centre for Defence Medicine, Birmingham, UK
    Search for more papers by this author
  • Eric Caumes MD,

    1. TropNet, European Network for Tropical Medicine and Travel Health, Basel, Switzerland
    2. Service de Maladies Infectieuses et Tropicales, Hôpital Pitié Salpêtrière, Paris, France
    Search for more papers by this author
  • Jan Clerinx MD,

    1. TropNet, European Network for Tropical Medicine and Travel Health, Basel, Switzerland
    2. Institute of Tropical Medicine, Antwerp, Belgium
    Search for more papers by this author
  • Pieter P.A.M. van Thiel MD,

    1. Center for Tropical and Travel Medicine, University of Amsterdam, Amsterdam, The Netherlands
    Search for more papers by this author
  • Gloria Morizot MD,

    1. UMRs945 INSERM UPMC Immunity & Infection, Paris, France
    Search for more papers by this author
  • Christoph Hatz MD,

    1. Swiss Tropical and Public Health Institute, Basel, Switzerland
    2. University of Basel, Basel, Switzerland
    3. TropNet, European Network for Tropical Medicine and Travel Health, Basel, Switzerland
    Search for more papers by this author
  • Thomas P.C. Dorlo,

    1. Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    Search for more papers by this author
  • Diana N.J. Lockwood MD

    1. London School of Hygiene & Tropical Medicine, London, UK
    Search for more papers by this author

Abstract

Background

Treatment of cutaneous leishmaniasis (CL) and mucosal leishmaniasis (ML) in travelers is still controversial. Over the last decade, national and international consortia have published recommendations for treating CL in travelers. These guidelines harmonize many issues, but there are some discrepancies.

Methods

Leishmania parasites causing CL can now be genotyped by polymerase chain reaction techniques for detecting Leishmania DNA. Therefore, treatment recommendations can now be species based rather than based on geographical exposure. To review the evidence on which the recommendations were based, “LeishMan” (Leishmaniasis Management), a group of experts from 13 institutions in eight European countries, performed a PubMed (MEDLINE) literature search and considered unpublished evidence and the experts' own personal experiences. The Oxford evidence grading system was used to evaluate the information.

Results and Conclusion

In this article, the authors provide practical treatment recommendations for imported CL and ML in Europe, drawn up from the review by the European experts.

Ancillary